In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Cancer Center Research Highlights
St. Jude Children’s Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.
Michael Kastan, MD, PhD, and Mary Relling, PharmD, of St. Jude Children’s Research Hospital, have been elected to the Institute of Medicine (IOM), a prestigious branch of the National Academy of Sciences.
Four years after Brenda Schulman, PhD, Structural Biology and Genetics and Tumor Cell Biology, set out to explore the universe within the APC, her team recently sent back its first dispatch from the frontier.
Cell death and survival will be the focus when the Fifth Annual St. Jude Biomedical Research Symposium opens Monday, October 5, with a talk by the scientist who led work on an experimental drug that aims to get cancer cells to self destruct.
A team led by St. Jude researchers recently identified a gene pivotal for immune system balance. Ultimately, the discovery may aid efforts to tame allergies and asthma.
St. Jude took another step in the shift from paper to electronic health records August 19 when chemotherapy orders from the Solid Tumor Clinic stopped coming in by fax and began arriving in the pharmacy electronically.
Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.
The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesting the cancer arises from just a handful of missteps, according to new findings from St. Jude Children’s Research Hospital.
The most comprehensive study yet of long-term survivors of childhood central nervous system (CNS) tumors details risks some survivors face decades after their diagnosis, prompting a renewed call for improved follow-up care.
Efforts to harness natural killer (NK) cells for cancer treatment advanced recently thanks to a St. Jude strategy that dramatically boosts production of the powerful, but rare immune component.
Charles Mullighan, MD, PhD, an assistant member in the Pathology Department at St. Jude Children’s Research Hospital, has been named a 2009 Pew Scholar in the Biomedical Sciences. He is the fourth St. Jude scientist honored.
A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death.
In a new study of adults who survived cancer as children, St. Jude researchers have found that many survivors lead sedentary lifestyles and are more likely to be less physically active than their siblings.
Every cell in the body arises from the process of cell division—an intricate molecular process in which a cell precisely copies its gene-containing chromosomes and segregates them into identical parcels that migrate into the two new daughter cells. Malfunction of this segregation machinery can have profound consequences.
Scientists have found evidence suggesting that small-molecule drugs could offer the first effective chemotherapy for childhood low-grade astrocytomas, improving the prognosis for hundreds of children with the disease.
Immunologists have made great strides in enlisting the body’s own immune cells to fight cancers and infections.
Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.
Researchers at St. Jude have demonstrated for the first time that tiny molecules called microRNAs participate in the initiation and progression of one form of human medulloblastoma, the most common malignant brain cancer in children.
The p53 protein plays an immensely important role in protecting the body from cancer. Dubbed the cell’s guardian of the genome, p53 is constantly poised to detect potentially tumor-causing DNA damage.
Oncologists frequently use combinations of chemotherapy drugs as a knockout punch against tumors. The strategy has proven successful because it aims to jam the machinery of cancer cells in ways that are synergistic—fighting cancers more effectively than the individual drugs could alone.
Scientists at St. Jude have generated new models of medulloblastoma tumors by inactivating different DNA repair pathways, specifically in the brain.
For the first time, St. Jude researchers have identified a subtype of acute T-lymphoblastic leukemia (T-ALL) that is resistant to standard chemotherapy. They are planning to use this new insight to diagnose the disease in children with the subtype and to use bone marrow transplants to more effectively treat the disease.
Even though women treated for childhood cancers with chest radiation suffer a high risk of breast cancer, they are far less likely to begin recommended early mammogram screening than they should, researchers found.
Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia.
St. Jude researchers have discovered a chain of biochemical events that compromise the liver’s capacity to adequately clear many prescription drugs from the bodies of fetuses, young children and patients with liver cancer and other hepatic disorders.
St. Jude scientists have answered a central question in cancer biology: whether normal stem cells can give rise to tumors.
Scientists at St. Jude have identified distinctive genetic changes that cause relapse in children with acute lymphoblastic leukemia (ALL).
St. Jude Children’s Research Hospital recently received the prestigious recognition of being designated as a National Cancer Institute (NCI) Comprehensive Cancer Center. The designation makes St. Jude the first and only cancer center solely focused on pediatric cancer to receive this distinction.
